Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
This was great NEWS https://finance.yahoo.com/news/lexicon-pharmaceuticals-enters-agreement-tersera-111000543.html
One more good PR should send this over $3 hopefully we hear something soon.
Took some 1.83's. Not sure if it's just overall market taking its toll here or the "sell on news" thing. I'm a buyer here.
See where this is come Fall. HIGHER!!! IMO
OK ENOUGH of the BULLSHIT, UP is where this should be GOING NOT DOWN.
News: $LXRX Lexicon Pharmaceuticals Inc (LXRX) Q2 2020 Earnings Call Transcript
Image source: The Motley Fool. Lexicon Pharmaceuticals Inc (NASDAQ: LXRX) Q2 2020 Earnings Call Jul 30, 2020 , 8:00 a.m. ET Operator Continue reading
Got this from LXRX - Lexicon Pharmaceuticals Inc (LXRX) Q2 2020 Earnings Call Transcript
News: $LXRX Lexicon Realigns Business Around Research and Development Assets, with Focus on Phase 2 LX9211 Neuropathic Pain Program
Phase 2 Study for Diabetic Peripheral Neuropathic Pain Underway, Additional Studies Planned in Other Areas of Neuropathic Pain Sale of XERMELO to TerSera to Yield Up to $224 Million in Upfront and Milestone Payments Plus Mid-Teens Royalties on Net Sales of XERMELO in Biliary Tract C...
Find out more LXRX - Lexicon Realigns Business Around Research and Development Assets, with Focus on Phase 2 LX9211 Neuropathic Pain Program
News: $LXRX Lexicon Pharmaceuticals Enters Into Agreement With TerSera Therapeutics for the Sale of XERMELO
THE WOODLANDS, Texas and DEERFIELD, Ill., July 30, 2020 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) and TerSera Therapeutics LLC announced today that they have entered into an asset purchase and sale agreement for the sale to TerSera of Lexicon’s rights, titl...
Read the whole news LXRX - Lexicon Pharmaceuticals Enters Into Agreement With TerSera Therapeutics for the Sale of XERMELO
News: $LXRX Lexicon Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides a Business Update
THE WOODLANDS, Texas, July 30, 2020 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results and provided a business update for the three months ended June 30, 2020. “We achieved 21% growth in XERMELO net sales in the U.S. for the seco...
Find out more LXRX - Lexicon Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides a Business Update
Half or more the shares outstanding as well.
* * $LXRX Video Chart 07-30-2020 * *
Link to Video - click here to watch the technical chart video
Bottom in at 1.89 resistance level 2.00
Trump announced it that’s the difference
Good news in a bad day, if it was any other day could be over $3 dollars by now, but anyway we will get there very soon .
"Lexicon to Receive Up to $224 Million in Upfront and Milestone Payments Plus Mid-Teens Royalties on Net Sales of XERMELO in Biliary Tract Cancer"
https://finance.yahoo.com/news/lexicon-pharmaceuticals-enters-agreement-tersera-111000543.html
And its barely moving and KODK gets a 700M + LOAN and it rockets up 100's of percentages.
What am I missing ?
LXRX huge news out: 224 million dollars upfront payment
https://finance.yahoo.com/news/lexicon-realigns-business-around-research-111500415.html
* * $LXRX Video Chart 07-21-2020 * *
Link to Video - click here to watch the technical chart video
Yeah... it is leaves it in Limbo though... so if no partner... then it is going nowhere.
They could have worded that differently. Like "LXRX seeks strategic partnership for commercialization".
The market is certainly big enough that some mid to big pharma may be interested. Possibly why they're saving some of the juice upcoming medical congresses and publications.
Nice to see some action here though, that's for sure!!
I thought this was interesting
Lexicon does not intend to pursue any regulatory approvals of sotagliflozin for type 2 diabetes in the absence of a strategic partnership for the commercialization of sotagliflozin in such indication.
So why even do a Phase 3 trial? Do they think they will get a partner to bring this commercialization?
NEWS! http://www.lexpharma.com/media-center/news/748-lexicon-pharmaceuticals-announces-topline-phase-3-data-from-four-phase-3-sotagliflozin-studies-in-type-2-diabetes
I'm guessing 3.50 - $4 target for now. I'll be adding if this even tries to fill the gap.
why selling the whole time 1 stock.
I don't understand this kind or selling
Yes. They still have a lot going for them. And like they mentioned, they should have enough data to get top line results after the follow ups.
Smart move they realized the likelihood of a partnership right now is highly unlikely so they will save money and focus on their other trials . But I do see this one on hold will definitely have a lot of interest in it . And already approved in Europe so time will tell
“We will provide further information regarding the close-out of the studies on our first quarter results conference call in early May. Pending review of the data, we expect that we will have accrued sufficient exposure data and cardiovascular events to satisfy all requirements for type 2 diabetes and, even with the early close-out, that these studies will contribute scientifically important data in the areas of cardiovascular and chronic kidney disease. Importantly, this shift allows us to conserve our financial resources and to prioritize our portfolio to advance pipeline initiatives such as telotristat ethyl in biliary tract cancer and LX9211 in neuropathic pain.”
http://www.lexpharma.com/media-center/news/740-lexicon-pharmaceuticals-provides-an-update-on-the-sotagliflozin-type-2-diabetes-program
COVID-19 is likely messing with many many companies trials.
Roll with it or not.
I see the manipulation all to often. Though I have seen some make the mistake of having an open order without using the "All or None" which allows the MM's to chase in either direction above or below the bid and they nip just 1 share out of the order to do it. Bad pool imo. At least those individuals aren't being charged a transaction fee anymore for a trade. At least most houses aren't charging for trades anymore.
As for LXRX, I'm waiting to see if this holds the $2 mark or dips below to try and fill the gap around 1.75. I'm still trying to accumulate here and this market "environment" is certainly helping.
-----------------
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), will release its fourth quarter and full-year 2019 financial results on Thursday, March 12, 2020 before market opens. Management will conduct a conference call and live webcast at 8:00 a.m. EST (7:00 a.m. CST) that day to discuss the financial results and to provide a business update.
Dial-in Information
U.S. Dial-in Number: (888) 645-5785
International Dial-in Number: (970) 300-1531
Conference ID: 4187725
Replay Information
U.S. Dial-in Number: (855) 859-2056
Replay International Dial-in Number: (404) 537-3406
Conference ID: 4187725
I believe those trades with one share is a short who is trying to reduce the price value and is seemingly making the price of the stock lower pre market and after hours. I just don’t quite understand how the buy volume has consistently been if not twice the sell volume and not seeing the price mature to what the buy volume is
Look at the share lots. Many trades only 1 share? Really?
There is a gap under $2, not that I expect it to fill but this market is nuts.
Let reality set in and get this virus under control and see what happens.
Damn I just added last week to my position thinking adding a a couple thousand more shares at 2.72 thought that was going to be the bottom but this market has been so unpredictable
Bios are more event reaction based. That's what makes them so volatility near their catalyst. This could go as far as to fill the gap under $2 which may explain some of the pressure though anything can turn this back up on a hurry. Anything major and it's over $10.
Institutional holdings, and insiders believe imo. This will be a major move imo. I just like the charts, and I am a buyer.
Cheers.
I don’t know dude all the indicators tell me that their is a whole lot more buying than selling going on but the price of the stock keeps on going down. Their is a lot of institutional activity going on on a daily basis.
Yeah that my plan I bought In at 4.15 $ and thought it made sense to dd at 3.06$ but I feel compelled to buy some more if it stays in this price area their has been a massive amount of institutional ownership increase today and wondered why would the stock price be declining at this percent and since the past few weeks and am baffled especially with all of those insider purchases on Wednesday . Their are too many hedge funds in the institutional ownership percentage that are selling shorts
The float is tight, no doubt. This really adds to the potential volatility. LXRX can be sitting @ $3 one minute and cruise right back to $5 easily on good news.
My plan has been to watch for a solid bottom, double bottom at the moment. I like watching the charts but they mean squat if the right news hits. Thinking this bio is an excellent target for big pharma.
Anyway, I'm looking to take a more solid position soon. See if $3 holds or it dips below.
I’ve. Been adding on to my position. For a couple of weeks I feel something big is around the corner and their earnings are going to be good . My only issue is that I think their is way too much institutional ownership that is preventing it from blowing up
Starting to get the itch. Watching closer.
Excellent. Data from a retrospective, pre- and post-design chart review of 200 metastatic neuroendocrine tumor patients who were on standard background therapies and received telotristat ethyl for an average of 12 months in US clinical practice demonstrated significant mean tumor size reduction of 0.59 cm after initiation of telotristat ethyl (p = 0.006).
http://www.lexpharma.com/media-center/news/736-lexicon-pharmaceuticals-announces-real-world-data-on-telotristat-ethyl-s-antiproliferative-effects-in-patients-with-carcinoid-syndrome
Maybe, just maybe. I know what real longs are looking for here.
Maybe it's game on next week.
Cheers!
Btw, I like my charts but I always like a winner.
Back in long @ 3.34. See how it goes. Can add if it goes under $3. But just may catch some momentum next week.
On radar. Possible squeeze down.
Small response to this sale maybe?
https://ih.advfn.com/stock-market/NASDAQ/lexicon-pharmaceuticals-LXRX/stock-news/81546285/current-report-filing-8-k
Presentation Friday so any dip may be short lived.
https://ih.advfn.com/stock-market/NASDAQ/lexicon-pharmaceuticals-LXRX/stock-news/81562626/lexicon-pharmaceuticals-announces-poster-presentat
On radar. Possible squeeze down.
Small response to this sale maybe?
https://ih.advfn.com/stock-market/NASDAQ/lexicon-pharmaceuticals-LXRX/stock-news/81546285/current-report-filing-8-k
Presentation Friday so any dip may be short lived.
https://ih.advfn.com/stock-market/NASDAQ/lexicon-pharmaceuticals-LXRX/stock-news/81562626/lexicon-pharmaceuticals-announces-poster-presentat
LXRX is overdue for another multi dollar run above to $6.00 to $8.00 soon IMO. 96% owned by institutions so the float is low enough for big $$$ soon IMO!
96% of the LXRX OS is owned by institutions so the tiny float left can move up multi dollars fast as we have seen.
There was a lot of crazy shorting happening after that pre market run to $6.40 last week. Then they took LXRX down red on a good news day. Day traders always screw up good runs they sell on any red so shorts play them well. They buy then sell minutes later all day long like we saw so all the huge volume means nothing. Looking forward to the next squeeze above.
$LXRX bears and bulls Lexicon Pharmaceuticals Inc Nasdaq Lxrx Short Squeeze
Probably the sell on news thing eh?
Followers
|
55
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
770
|
Created
|
02/27/05
|
Type
|
Free
|
Moderators |
Sotagliflozin Significantly Reduced Total Cardiovascular Deaths, Heart Failure Hospitalization and Urgent Visits, Achieving Primary Endpoint in Both Studies
THE WOODLANDS, Texas, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today announced that both the SOLOIST and SCORED Phase 3 studies achieved their primary endpoints by demonstrating statistically significant reductions in total cardiovascular deaths, hospitalizations for heart failure and urgent heart failure visits in patients treated with sotagliflozin as compared with placebo.
In the SOLOIST study, the primary endpoint was achieved with a hazard ratio (HR) of 0.67 (p<0.001) in people with type 2 diabetes and a recent hospitalization for worsening heart failure. In the SCORED study, the primary endpoint was achieved with a hazard ratio of 0.74 (p<0.001) in people with type 2 diabetes and chronic kidney disease with an estimated glomerular filtration rate (eGFR) of 25 to 60 ml/minute per 1.73 m² of body-surface area.
The key results from SOLOIST and SCORED were presented today at the Late-Breaking Science Session of the American Heart Association (AHA) Scientific Sessions 2020 and simultaneously published in The New England Journal of Medicine (NEJM) in two separate articles titled: “Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure” and “Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease.” The articles may be accessed at www.nejm.org.
“Cardiovascular disease continues to be a leading cause of death in people with type 2 diabetes,” said Deepak L. Bhatt, M.D., M.P.H., executive director of Interventional Cardiovascular Programs at Brigham and Women's Hospital and a professor of medicine at Harvard Medical School and study chair and lead author for the NEJM publications of the SOLOIST and SCORED results. “SOLOIST demonstrates that early, in-hospital initiation of sotagliflozin in patients with worsening heart failure significantly reduces subsequent cardiovascular events, an effect that was consistent across groups with heart failure with reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction (HFpEF). SCORED demonstrates that sotagliflozin significantly reduces heart failure events in a patient population with stage 3 and 4 chronic kidney disease and cardiovascular risk. Both studies add to the evidence that SGLT2 inhibition should be standard of care in heart failure, and the SCORED data reflecting a reduction in myocardial infarction and stroke and better glucose control in CKD patients suggest potential benefits from the dual SGLT1 and SGLT2 mechanism of this particular agent.”
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |